PCYC-1106-CA: Safety and Efficacy of BTK Inhibitor in Subjects with Relapsed or Refractory Non-Hodgkin’s Diffuse Large B-cell Lymphoma
To access the most up-to-date information on this study,
please refer to this page at ClinicalTrials.gov.
A Multicenter, Open-label, Phase II, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this study is to establish the safety and efficacy of PCI-32765 in patients with Non-Hodgkin diffuse large B-cell lymphoma (DLBCL).